Anti-CD19 chimeric antigen receptor T cell therapy - Takara Bio

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Takara Bio

Alternative Names: CD19 CAR gene transduced T lymphocytes - Takara Bio; CD19 chimeric antigen receptor T cell therapy - Takara Bio; CD19-CAR gene therapy - Takara Bio; CD19-CAR T cell therapy - Takara Bio; TBI-1501

Latest Information Update: 11 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Jichi Medical School; Takara Bio
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 10 Apr 2018 Otsuka Pharmaceutical and Takara Bio agree to co-promote [and co-develop] TBI 1301 in Japan for Cancer
  • 19 May 2017 Takara Bio plans a phase I/II trial for Acute lymphoblastic leukaemia (Second-line therapy or greater) in Japan (NCT03155191)
  • 29 Dec 2016 CD19 Chimeric Antigen Receptor T cell therapy is still in phase I/II trials for Non-Hodgkin's lymphoma (Second-line therapy or greater) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top